passages.id: PMC-2690976-sec-05__text
passages.type: sec
passages.text: Efficacy of MMF in current immunosuppressive regimens after kidney transplantation
  Current established immunosuppressive strategies in kidney transplantation often include an induction agent (monoclonal or polyclonal anti-T-cell antibodies) based on the immunologic risk of the recipient, followed by a maintenance regimen combining a CNI and an anti-proliferative agent, with or without corticosteroids.2-4 As MMF was the first MPA formulation approved in clinical kidney transplantation, more extensive clinical data are available with this drug in comparison to EC-MPS.
  
  